Results 21 to 30 of about 15,210 (229)
Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]
, 2017 Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S. +3 more
core +1 more source
Oral hypomethylating agents: beyond convenience in MDS
Hematology, 2021 AbstractOral hypomethylating agents (HMAs) represent a substantial potential boon for patients with myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per month to an infusion clinic to receive therapy. For patients who respond to treatment, ongoing monthly maintenance visits represent a considerable burden to quality of
openaire +3 more sources
Haematologica, 2020 In older patients with acute myeloid leukemia, the more frequent presence of biologically inherent therapy-resistant disease and increased comorbidities translate to poor overall survival and therapeutic challenges. Optimal front-line therapies for older
Chetasi Talati +11 more
doaj +1 more source
An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
Clinical Case Reports, 2023 Key Clinical Message Hypomethylating agents may be useful in some but not all cases of myelodysplastic syndromes. In some versions of these conditions, this treatment may yield deleterious results.
Anwarul Islam
doaj +1 more source
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia [PDF]
Cell Cycle, 2011 The deregulation of the DNA damage response (DDR) can contribute to leukemogenesis and favor the progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML). Since hypomethylating agent, notably azacitidine, constitute an efficient therapy for patients with high-risk MDS, we assessed whether such compounds can activate the DDR in ...
Thépot, Sylvain +16 more
openaire +3 more sources
Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia
Biomarker Insights, 2019 Epigenetic alteration has been proposed to give rise to numerous classic hallmarks of cancer. Impaired DNA methylation plays a central role in the onset and progression of several types of malignancies, and DNA methylation is mediated by DNA ...
Kah Keng Wong +2 more
doaj +1 more source
Haematologica, 2010 Hypomethylating agents have recently been shown to improve the outcome of patients with myelodysplastic syndrome. A meta-analysis and systematic review was carried out of randomized controlled trials comparing treatment with hypomethylating agents to ...
Ronit Gurion +6 more
doaj +1 more source
Protein glycosylation in sugar beet cell line can be influenced by DNA hyper- and hypomethylating agents [PDF]
, 2012 Protein glycosylation is a co- and post-translational modification that influences protein function, stability and localization. Changes in glycoprotein pattern during differentiation/dedifferentiation events exist in animal cells and DNA methylation ...
Dubravko Pavoković +1 more
core +2 more sources
The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer [PDF]
, 2014 PURPOSE: To investigate SGI-110 as a "chemosensitizer" in ovarian cancer and to assess its effects on tumor suppressor genes (TSG) and chemoresponsiveness-associated genes silenced by DNA methylation in ovarian cancer.
Azab, Mohammad +15 more
core +1 more source
Novel therapeutic strategies: hypomethylating agents and beyond [PDF]
Hematology, 2012 Abstract The treatment of symptomatic and high-risk myelodysplastic syndrome (MDS) spans several therapeutic goals and options. Key to the successful therapy of these heterogeneous diseases is careful characterization and diagnosis, including clinical, cytogenetic, biological, and molecular evaluation of individual patients.
openaire +2 more sources